MCID: MTR004
MIFTS: 57

Maturity-Onset Diabetes of the Young malady

Categories: Genetic diseases, Rare diseases, Endocrine diseases, Neuronal diseases

Aliases & Classifications for Maturity-Onset Diabetes of the Young

About this section

Aliases & Descriptions for Maturity-Onset Diabetes of the Young:

Name: Maturity-Onset Diabetes of the Young 11 47 24 53 26 13
Mody 11 47 53
Maturity Onset Diabetes Mellitus in Young 67
 
Mason-Type Diabetes 11
Mason Type Diabetes 47

Characteristics:

Orphanet epidemiological data:

53
maturity-onset diabetes of the young:
Inheritance: Autosomal dominant,Not applicable; Prevalence: 1-5/10000 (Europe),1-5/10000 (United Kingdom); Age of onset: Adolescent,Adult,Childhood

Classifications:



External Ids:

Disease Ontology11 DOID:0050524
ICD1029 E11.8
Orphanet53 ORPHA552
ICD10 via Orphanet30 E11.9

Summaries for Maturity-Onset Diabetes of the Young

About this section
Wikipedia:70 Maturity onset diabetes of the young (MODY) refers to any of several hereditary forms of diabetes caused... more...

MalaCards based summary: Maturity-Onset Diabetes of the Young, also known as mody, is related to maturity-onset diabetes of the young, type 13 and maturity-onset diabetes of the young, type viii. An important gene associated with Maturity-Onset Diabetes of the Young is GCK (Glucokinase), and among its related pathways are Dichloroethylene metabolism and Integration of energy metabolism. Affiliated tissues include bone, brain and testes, and related mouse phenotypes are digestive/alimentary and adipose tissue.

Disease Ontology:11 A genetic disease that has material basis in mutations in the MODY genes disrupting insulin production.

Related Diseases for Maturity-Onset Diabetes of the Young

About this section

Diseases in the Maturity-Onset Diabetes of the Young family:

Maturity-Onset Diabetes of the Young, Type Vii Maturity-Onset Diabetes of the Young 6
Maturity-Onset Diabetes of the Young, Type 14 Maturity-Onset Diabetes of the Young, Type Ix
Maturity-Onset Diabetes of the Young, Type 11 Maturity-Onset Diabetes of the Young, Type Viii
Maturity-Onset Diabetes of the Young, Type 10 Maturity-Onset Diabetes of the Young, Type 13

Diseases related to Maturity-Onset Diabetes of the Young via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 59)
idRelated DiseaseScoreTop Affiliating Genes
1maturity-onset diabetes of the young, type 1334.4ABCC8, KCNJ11
2maturity-onset diabetes of the young, type viii12.7
3maturity-onset diabetes of the young 612.7
4maturity-onset diabetes of the young, type vii12.7
5maturity-onset diabetes of the young, type ix12.7
6maturity-onset diabetes of the young, type 1112.6
7maturity-onset diabetes of the young, type 1012.6
8maturity-onset diabetes of the young, type 1412.6
9fanconi renotubular syndrome 4, with maturity-onset diabetes of the young12.6
10renal cysts and diabetes syndrome12.2
11mody, type i12.1
12mody, type iii12.1
13mody, type iv12.1
14mody, type ii12.0
15diabetes mellitus, transient neonatal, 111.0
16fanconi renotubular syndrome 111.0
17neonatal diabetes mellitus10.5GCK, INS, KCNJ11
18rectum signet ring adenocarcinoma10.5FOXA2, NEUROG3
19biliary cirrhosis, primary, 510.5HNF1B, HNF4A
20writing disorder10.3ABCC8, GCK, KCNJ11
21toxic megacolon10.3ABCC8, GCK, INS, KCNJ11
22diabetes mellitus, transient neonatal, 310.3ABCC8, INS, KCNJ11
23pancreatitis10.3
24usher syndrome, type 1c10.3ABCC8, KCNJ11
25retinitis pigmentosa 6810.3ABCC8, INS, SLC2A2
26acute insulin response10.3ABCC8, INS, KCNJ11
27perlman syndrome10.3ABCC8, GCK, KCNJ11
28patellofemoral pain syndrome10.3ABCC8, GCK, INS, KCNJ11
29diaphanospondylodysostosis10.3ABCC8, GCK, INS, KCNJ11, PDX1
30inclusion body myopathy with paget disease of bone and frontotemporal dementia10.3ABCC8, GCK, INS, KCNJ11, PDX1
31short bowel syndrome10.2ABCC8, GCK, INS, KCNJ11
32hyperlipoproteinemia type iv10.2ABCC8, GCK, INS, KCNJ11, PDX1
33anatomical narrow angle borderline glaucoma10.2ABCC8, GCK, HNF4A, INS, KCNJ11
34gestational choriocarcinoma10.2ABCC8, GCK, HNF4A, INS, KCNJ11
35hypoglycemia10.2
36intraocular lymphoma10.2ABCC8, GCK, INS, NEUROD1, SLC2A2
37hepatitis10.2
38nephronophthisis 1910.2ABCC8, INS, KCNJ11
39femoral neuropathy10.2ABCC8, GCK, INS, KCNJ11, SLC2A2
40survival motor neuron spinal muscular atrophy10.2ABCC8, GCK, INS, KCNJ11, SLC2A2
41hemimegalencephaly10.2ABCC8, KCNJ11
42hypertrichosis10.1ABCC8, GCK, HNF1A, INS, KCNJ11, SLC2A2
43duodenitis10.0
44obesity9.9
45hyperglycemia9.9
46proximal chromosome 18q deletion syndrome9.9ABCC8, CEL, GCK, HNF1A, HNF1B, HNF4A
4718p deletion syndrome9.8ABCC8, GCK, KCNJ11
48colorectal cancer9.8
49hepatocellular carcinoma9.8
50granuloma annulare9.8

Graphical network of the top 20 diseases related to Maturity-Onset Diabetes of the Young:



Diseases related to maturity-onset diabetes of the young

Symptoms for Maturity-Onset Diabetes of the Young

About this section

Drugs & Therapeutics for Maturity-Onset Diabetes of the Young

About this section

Drugs for Maturity-Onset Diabetes of the Young (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 241)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1MoxonidineapprovedPhase 41375438-57-24810
2
GlimepirideapprovedPhase 4, Phase 2, Phase 323093479-97-13476
Synonyms:
1-((p-(2-(3-Ethyl-4-methyl-2-oxo-3-pyrroline-1-carboxamido)ethyl)phenyl)sulfonyl)-3-(trans-4-methylcyclohexyl)urea
1-{[4-(2-{[(3-ethyl-4-methyl-2-oxo-2,5-dihydro-1H-pyrrol-1-yl)carbonyl]amino}ethyl)phenyl]sulfonyl}-3-(trans-4-methylcyclohexyl)urea
3-ethyl-4-methyl-N-[2-(4-{[(trans-4-methylcyclohexyl)carbamoyl]sulfamoyl}phenyl)ethyl]-2-oxo-2,5-dihydro-1H-pyrrole-1-carboxamide
3-ethyl-4-methyl-n-(4-(n-((1r,4r)-4-methylcyclohexylcarbamoyl)sulfamoyl)phenethyl)-2-oxo-2,5-dihydro
4-ethyl-3-methyl-N-[2-[4-[(4-methylcyclohexyl)carbamoylsulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide
64598P
93479-97-1
AB00513874
AC-476
AC1L1G0T
Amarel
Amaryl
Amaryl (TN)
Amaryl, Glista OD, Glimepiride
Avaglim
BPBio1_000751
BRD-K34776109-001-03-4
BRD-K42693031-001-01-8
BRN 5365754
BSPBio_000681
Bio-0049
C07669
C24H34N4O5S
CAS-93479-97-1
CCRIS 7083
CHEBI:5383
CHEMBL1481
CID3476
CPD000466368
D00593
DB00222
Endial
G2295_SIGMA
Glimepirid
Glimepirida
Glimepirida [Spanish]
Glimepiride (JAN/USP/INN)
Glimepiride [USAN:BAN:INN]
Glimepiridum
Glimepiridum [Latin]
 
Glimepride
Glimer
Glimépiride
Glymepirid
HMS1570C03
HMS2052L03
HMS2090K18
HOE 490
Hoe-490
I06-0029
I06-2285
LS-136752
MLS000759495
MLS001076674
MLS001401419
MolPort-003-847-587
MolPort-003-987-461
MolPort-005-941-721
NCGC00016960-01
NCGC00161404-01
NCGC00161404-02
NCGC00181757-01
Novo-glimepiride
Oprea1_382896
PMS-glimepiride
Prestwick0_000651
Prestwick1_000651
Prestwick2_000651
Prestwick3_000651
Ratio-glimepiride
Roname
S1344_Selleck
SAM001246710
SMR000466368
SPBio_002602
Sandoz glimepiride
Solosa
TL8005924
UNII-6KY687524K
ZINC00537791
glimepiride
3
EthanolapprovedPhase 4204364-17-5702
Synonyms:
(C6-C9)Alkyl alcohol
02483_FLUKA
02851_FLUKA
02853_FLUKA
02854_FLUKA
02855_FLUKA
02856_FLUKA
02856_SIAL
02857_FLUKA
02857_SIAL
02858_FLUKA
02858_SIAL
02860_FLUKA
02865_FLUKA
02865_SIAL
02870_FLUKA
02870_SIAL
02875_FLUKA
02877_FLUKA
02878_FLUKA
02882_FLUKA
02882_SIAL
02883_FLUKA
02884_FLUKA
02890_FLUKA
02890_SIAL
02891_FLUKA
02891_SIAL
1-Hydroxyethane
100C.NPA
121182-78-3
187380_ALDRICH
187380_SIAL
24102_RIEDEL
24102_SIAL
24103_RIEDEL
24103_SIAL
24105_RIEDEL
24105_SIAL
24106_RIEDEL
24106_SIAL
24194_RIEDEL
24194_SIAL
245119_ALDRICH
245119_SIAL
270741_ALDRICH
270741_SIAL
277649_ALDRICH
277649_SIAL
2858_SIGMA
29221_FLUKA
32205_RIEDEL
32205_SIAL
32221_RIEDEL
32221_SIAL
32294_RIEDEL
32294_SIAL
34870_SIAL
34963_RIEDEL
39278_FLUKA
40210_ALDRICH
40210_RIEDEL
41322_FLUKA
458600_ALDRICH
458600_SIAL
459828_ALDRICH
459828_SIAL
459836_ALDRICH
459836_SIAL
459844_SIAL
48075_SUPELCO
493511_SIAL
493538_ALDRICH
493538_SIAL
493546_ALDRICH
493546_SIAL
64-17-5
676829_SIAL
68475-56-9
71076-86-3
71329-38-9
8000-16-6
8024-45-1
AC1L19TW
AC1Q31MM
AHD 2000
AI3-01706
ALCOHOL 5% IN D5-W
Absolute Alcohol
Absolute Ethanol
Absolute alcohol
Absolute ethanol
Absolute ethyl alcohol
Aethanol
Aethanol [German]
Aethylalkohol
Alcare Hand Degermer
Alcohol
Alcohol (USP)
Alcohol (ethyl)
Alcohol Anhydrous
Alcohol [USP]
Alcohol anhydrous
Alcohol dehydrated
Alcohol denatured
Alcohol etílico
Alcohol, Absolute
Alcohol, Dehydrated
Alcohol, Diluted
Alcohol, Grain
Alcohol, anhydrous
Alcohol, dehydrated
Alcohol, denatured
Alcohol, diluted
Alcohol, ethyl
Alcohols
Alcohols, C1-3
Alcohols, C30
Alcohols, C6-9
Alcool Ethylique
Alcool Etilico
Alcool ethylique
Alcool etilico
Alcool éthylique
Algrain
Alkohol
Alkohol [German]
Alkoholu Etylowego
Alkoholu etylowego
Aminoethanol
Anhydrol
Anhydrol PM 4085
Anhydrous alcohol
Anhydrous ethanol
Beta-Aminoethanol
Beta-Aminoethyl Alcohol
Beta-Ethanolamine
Beta-Hydroxyethylamine
C00469
C2H5OH
C2H6O
CCRIS 945
CDA 19
CDA 19-200
CHEBI:16236
CHEMBL545
CID702
Caswell No. 426
Caswell No. 430
Colamine
Cologne Spirit
Cologne spirit
Cologne spirits
 
D000431
D00068
DB00898
Dehydrated Ethanol
Dehydrated alcohol
Dehydrated ethanol
Denatured Alcohol
Denatured Alcohol Cd-10
Denatured Alcohol Cd-5
Denatured Alcohol Cd-5a
Denatured Alcohol Sd-1
Denatured Alcohol Sd-13a
Denatured Alcohol Sd-17
Denatured Alcohol Sd-23a
Denatured Alcohol Sd-28
Denatured Alcohol Sd-30
Denatured Alcohol Sd-39b
Denatured Alcohol Sd-39c
Denatured Alcohol Sd-3a
Denatured Alcohol Sd-40m
Denatured Ethanol
Denatured alcohol
Denatured ethanol
Desinfektol EL
Diluted Alcohol
Distilled spirits
E2385_SIGMA
E7023_ALDRICH
E7023_SIAL
E7148_ALDRICH
E7148_SIAL
E7517_SIGMA
EINECS 200-578-6
EINECS 270-649-4
EOH
EOX
ETA
Envision Conditioner Pdd 9020
Esumiru WK 88
EtOH
Etanolo
Etanolo [Italian]
Ethanol (9CI)
Ethanol 200 Proof
Ethanol 200 proof
Ethanol Absolute
Ethanol Absolute Bp
Ethanol Anhydrous
Ethanol Extra Pure
Ethanol Vapor
Ethanol [JAN]
Ethanol solution
Ethanol, Silent Spirit
Ethanol, undenatured
Ethanolum anhydricum
Ethicap
Ethyl Alcohol
Ethyl Alcohol & Water, 10%
Ethyl Alcohol & Water, 20%
Ethyl Alcohol & Water, 30%
Ethyl Alcohol & Water, 40%
Ethyl Alcohol & Water, 5%
Ethyl Alcohol & Water, 50%
Ethyl Alcohol & Water, 60%
Ethyl Alcohol & Water, 70%
Ethyl Alcohol & Water, 80%
Ethyl Alcohol & Water, 95%
Ethyl Alcohol & Water, 96%
Ethyl Alcohol Anhydrous
Ethyl Alcohol, Anhydrous
Ethyl Alcohol, Denatured
Ethyl Hydrate
Ethyl Hydroxide
Ethyl alc
Ethyl alcohol
Ethyl alcohol anhydrous
Ethyl alcohol in alcoholic beverages
Ethyl alcohol usp
Ethyl hydrate
Ethyl hydroxide
Ethylalcohol
Ethylalcohol [Dutch]
Ethylol
Ethylolamine
Ethyloxy Group
Etylowy alkohol
FEMA No. 2419
FEMA Number 2419
Fermentation alcohol
Glycinol
Grain alcohol
HSDB 531
HSDB 82
HYDROXYETHYL GROUP
Hinetoless
Hydroxyethane
I14-12648
IMS 99
Infinity Pure
Jaysol
Jaysol S
LS-1539
LTBB002977
Lux
Methylated Spirit Mineralised
Methylated spirit
Methylcarbinol
MolPort-001-785-844
Molasses alcohol
NCGC00091458-01
NCI-C03134
NSC 85228
NSC85228
Oxydimethylene Group
Potato alcohol
Punctilious ethyl alcohol
Pyro
QMHAIh@
Reagent Alcohol
Ru-Tuss Expectorant
SDA 3A
SDA 40-2
SDM No. 37
SY Fresh M
Sekundasprit
Silent spirit
Spirit
Spirits of wine
Spiritus vini
Spirt
Synasol
Tecsol
Tecsol C
Thanol
Thiofaco M-50
UNII-3K9958V90M
USAF EK-1597
Undenatured Ethanol
WLN: Q2
absolute alcohol
alcohol
alcohol etilico
bmse000297
etanol
ethanol
ethyl alcohol
grain alcohol
nchem.651-comp3c
nchembio.552-comp10
nchembio.94-comp20
spiritus vini
Äthanol
Äthylalkohol
éthanol
4
Insulin AspartapprovedPhase 4442116094-23-616132418
Synonyms:
(AspB28)-human insulin
1024611-56-0
116094-23-6
139532-40-4
28(sup B)-L-Aspartic acid-insulin (human)
877034-90-7
AspB28-insulin (human)
Aspart
Aspart Insulin
Aspart insulin
B28-Asp-insulin
B28-Aspart-Insulin
INA-X 14
 
INA-X14
Insulin X14
Insulin aspart
Insulin aspart [USAN]
Insulin aspart protamine recombinant
Insulin aspart recombinant
Insulin, Asp(B28)
LS-185932
NovoLog
NovoMix 30
NovoRapid
NovoRapid 30 Mix
Novolog mix 70/30
UNII-D933668QVX
5
Insulin GlargineapprovedPhase 4522160337-95-1
Synonyms:
 
Insulin Glargine (rDNA origin)
Insulin glargine recombinant
6
PitavastatinapprovedPhase 465147511-69-1, 147526-32-76366718, 5282452
Synonyms:
( )-(3R,5S,6E)-7-(2-Cyclopropyl-4-(4-fluorophenyl)-3-quinolyl)-3,5-dihydroxy-6-heptenoic acid
(3R,5S,6E)-7-(2-Cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)-3,5-dihydroxyhept-6-enoic acid
(3R,5S,6E)-7-(2-Cyclopropyl-4-(p-fluorophenyl)-3-quinolyl)-3,5-dihydroxy-6-heptenoic acid
(3R,5S,E)-7-(2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)-3,5-dihydroxyhept-6-enoate
(E,3R,5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid
111GE002
147511-69-1
147526-32-7
2C25H23FNO4.Ca
AC1NR03G
AC1NR03J
AKOS005145916
Alipza
Bis((3R,5S,6E)-7-(2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl)-3,5-dihydroxy-6-heptenoate), monocalcium salt
C13334
CCRIS 8652
CID5282451
CID5282452
D01862
Itavastatin
Itavastatin calcium
KS-1220
LS-190698
 
LS-74594
LS-74595
Livalo
Livalo (TN)
Livalo, Pitavastatin calcium
Livazo
MolPort-006-822-984
NK 104
NK-104
NKS-104
Nisvastatin
P 872441
P-872441
Pitavastatia
Pitavastatin
Pitavastatin [INN]
Pitavastatin calcium
Pitavastatin calcium (JAN)
Pitavastatin hemicalcium
Pitavastatine
Pitavastatinum
S1759_Selleck
ZINC01534965
calcium (E,3R,5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoate
7
MetforminapprovedPhase 4, Phase 3, Phase 21746657-24-914219, 4091
Synonyms:
1,1-Dimethyl biguanide
1,1-Dimethylbiguanide
3-(diaminomethylidene)-1,1-dimethylguanidine
657-24-9
AC1L1HE4
AKOS000121065
Apo-Metformin
BIDD:GT0697
BPBio1_000009
BRD-K79602928-003-04-1
BSPBio_000007
BSPBio_002314
C07151
C4H11N5
CAS-1115-70-4
CCRIS 9321
CHEBI:6801
CHEMBL1431
CID4091
D04966
DB00331
DMGG
Diabetosan
Diabex
Dimethylbiguanid
Dimethylbiguanide
Dimethylbiguanidine
Dimethyldiguanide
Dimethylguanylguanidine
EINECS 211-517-8
Fluamine
Flumamine
Fortamet
Gen-Metformin
Glifage
Gliguanid
Glucophage
Glucophage XR
Glumetza
Glycon
HMS2089D19
HSCI1_000295
Haurymelin
Haurymellin
Islotin
KBio2_002310
KBio2_004878
KBio2_007446
KBio3_002790
KBioGR_002310
 
KBioSS_002312
LA-6023
LS-43899
Melbin
Metformin
Metformin (USAN/INN)
Metformin HCL
Metformin [USAN:INN:BAN]
Metformina
Metformina [DCIT]
Metformina [Spanish]
Metformine
Metformine [INN-French]
Metformine pamoate
Metforminum
Metforminum [INN-Latin]
Metiguanide
MolPort-002-929-560
MolPort-004-288-389
MolPort-005-767-418
Mylan-Metformin
N,N-Dimethylbiguanide
N,N-Dimethyldiguanide
N,N-Dimethylimidodicarbonimidic diamide
N,N-dimethylimidodicarbonimidic diamide
N1,N1-Dimethylbiguanide
NCGC00016564-01
NCGC00016564-02
NCGC00016564-03
NNDG
Novo-Metformin
Nu-Metformin
PMS-Metformin
Prestwick0_000004
Prestwick1_000004
Prestwick2_000004
Prestwick3_000004
Ran-Metformin
Ratio-Metformin
Riomet
S2483_Selleck
SPBio_001928
STK011633
Sandoz Metformin
Siofor
T5895664
Teva-Metformin
UNII-9100L32L2N
ZINC12859773
cMAP_000016
metformin
metformin hydrochloride
8
MentholapprovedPhase 4, Phase 323532216-51-516666
Synonyms:
(−
()-Menthol
(+)-Neo-menthol
(+)-p-Menthan-3-ol
(+-)-(1R*,3R*,4S*)-Menthol
(+-)-Menthol
(+/-)-Menthol
(+/-)-p-Menthan-3-ol
(-)-(1R,3R,4S)-Menthol
(-)-Menthyl alcohol
(-)-menthol
(-)-p-Menthan-3-ol
(-)-trans-p-Menthan-cis-ol
(1R)-(-)-Menthol
(1R,2S,5R)-(-)-menthol
(1R,2S,5R)-Menthol
(1R,3R,4S)-(-)-MENTHOL
(1R,3R,4S)-(-)-Menthol
(1R-(1-alpha,2-beta,5-alpha))-5-Methyl-2-(1-methylethyl)cyclohexanol
(1S, 2S, 5R)-(+)-Neomenthol
(1S,2R,5R)-(+)-Isomenthol
(1S,2R,5S)-(+)-Menthol
(1S,2R,5S)-Menthol
(1alpha,2beta,5alpha)-5-Methyl-2(1-methylethyl)cyclohexanol
(1r,2s,5r)-(-)-menthol
(L)-MENTHOL
(R)-(-)-Menthol
(r)-(-)-menthol
)-Menthol
--MENTHOL
1-Menthol
1490-04-6
15356-60-2
15356-70-4
15785_RIEDEL
15785_SIAL
19863P
2-Isopropyl-5-methylcyclohexanol
20747-49-3
2216-51-5
3-p-Menthol
4-Isopropyl-1-methylcyclohexan-3-ol
491-02-1
5-Methyl-2-(1-methylethyl)-cyclohexanol
5-Methyl-2-(1-methylethyl)cyclohexanol
5-methyl-2-(propan-2-yl)cyclohexanol
5-methyl-2-propan-2-ylcyclohexan-1-ol
551376_ALDRICH
551376_FLUKA
588733_ALDRICH
613290_ALDRICH
613290_FLUKA
63660_FLUKA
63670_ALDRICH
63670_FLUKA
63975-60-0
6C6A4A8C-A054-468C-A1F0-F29E39838CF2
89-78-1
98167-53-4
AC1L1B2E
AC1L28FR
AC1Q1NQ2
AC1Q2QQM
AI3-08161
AI3-52408
AKOS000119740
AR-1J3337
BB_NC-0057
BRN 1902288
BRN 3194263
BSPBio_003062
C00400
C10H20O
CCRIS 3728
CCRIS 375
CCRIS 4666
CCRIS 9231
CHEBI:15409
CHEBI:545611
CHEMBL256087
CHEMBL470670
CID1254
CID16666
Caswell No. 540
D-(-)-Menthol
D-p-Menthan-3-ol
D00064
D008610
D04849
D04918
DB00825
DivK1c_000820
EINECS 201-939-0
EINECS 207-724-8
EINECS 216-074-4
EINECS 218-690-9
EINECS 239-387-8
EINECS 239-388-3
EPA Pesticide Chemical Code 051601
FEMA No. 2665
Fisherman's friend lozenges
Fisherman's friend lozenges (TN)
HMS1922G13
HMS2092L14
HMS502I22
 
HSDB 5662
HSDB 593
Headache crystals
Hexahydrothymol
I06-1216
I14-7371
IDI1_000820
KBio1_000820
KBio2_000785
KBio2_003353
KBio2_005921
KBio3_002562
KBioSS_000785
L-(-)-Menthol
L-(-)-menthol
L-Menthol
L-menthol
LMPR0102090001
LS-2353
LS-57201
LS-886
LS-89531
LS-89533
Levomenthol
Levomenthol [INN:BAN]
Levomentholum
Levomentholum [INN-Latin]
Levomentol
M0321
M0545
M2772_SIAL
MENTHOL
MLS002207256
Menthacamphor
Menthol
Menthol (USP)
Menthol (VAN)
Menthol natural
Menthol natural, brazilian
Menthol racemic
Menthol racemique
Menthol racemique [French]
Menthol solution
Menthol, (1alpha,2beta,5alpha)-Isomer
Menthomenthol
Menthyl alcohol
MolPort-000-849-729
MolPort-001-793-392
NCGC00159382-02
NCGC00159382-03
NCGC00164247-01
NCGC00164247-02
NCI-C50000
NINDS_000820
NOOLISFMXDJSKH-KXUCPTDWBX
NSC 2603
NSC 62788
NSC2603
NSC62788
Neoisomenthol
Peppermint camphor
RACEMIC MENTHOL U.S.P.
Racementhol
Racementhol [INN:BAN]
Racementholum
Racementholum [INN-Latin]
Racementol
Racementol [INN-Spanish]
Racemic menthol
Robitussin Cough Drops
SDCCGMLS-0066659.P001
SMR001306785
SPBio_000869
SPECTRUM1503134
STK802468
Spectrum2_000855
Spectrum3_001561
Spectrum5_001060
Spectrum_000305
Tra-kill tracheal mite killer
U.S.P. Menthol
U.S.p. Menthol
UNII-BZ1R15MTK7
UNII-L7T10EIP3A
UNII-YS08XHA860
W266507_ALDRICH
W266523_ALDRICH
W266590_ALDRICH
WLN: L6TJ AY1&1 BQ D1
WLN: L6TJ AY1&1 DQ D1 -L
ZINC01482164
cis-1 ,3-trans-1,4-(+-)-menthol
cis-1,3-trans-1,4-(+-)-menthol
d,l-Menthol
d-Menthol
d-Neomenthol
dl-3-p-Menthanol
dl-Menthol
dl-Menthol (JP15)
l-(-)-Menthol
l-Menthol
l-Menthol (JP15)
l-Menthol (TN)
l-Menthol (natural)
nchembio862-comp1
p-Menthan-3-ol
rac-Menthol
9
Exenatideapproved, investigationalPhase 4, Phase 3, Phase 2289141758-74-915991534
Synonyms:
141732-76-5
141758-74-9
286014-72-0
335149-21-8
AC 2993
AC 2993 LAR
AC 2993A
AC-2993
AC002993
AC2993
AC2993a
Bydureon
Byetta
 
C074031
CHEBI:490990
CHEMBL414357
Ex4 peptide
Exenatide
Exenatide Synthetic
Exenatide synthetic
Exendin 4
Exendin 4 (Heloderma suspectum)
Exendin-4
Extendin-4
LY2148568
Synthetic exendin-4
UNII-9P1872D4OL
10
Insulin DetemirapprovedPhase 4196169148-63-45311023
Synonyms:
Detemir
 
Insulin detemir recombinant
Insulin,detemir,human
11
ZincapprovedPhase 4, Phase 3, Phase 122317440-66-632051, 23994
Synonyms:
30Zn
Cinc
Zinc
Zinc ion
 
Zincum
Zink
Zn
Zn(ii)
Zn2+
12
MirabegronapprovedPhase 489223673-61-8
Synonyms:
 
Myrbetriq
13
Aspirinapproved, vet_approvedPhase 4, Phase 2111250-78-22244
Synonyms:
11126-35-5
11126-37-7
1oxr
2-(ACETYLOXY)benzoic acid
2-(Acetyloxy)benzoate
2-(Acetyloxy)benzoic acid
2-Acetoxybenzenecarboxylic acid
2-Acetoxybenzoate
2-Acetoxybenzoic acid
2-Carboxyphenyl acetate
2349-94-2
26914-13-6
50-78-2
8-hour Bayer
98201-60-6
A 5376
A.S.A
A.S.A.
A.S.A. Empirin
A.S.A. empirin
A2093_SIGMA
A3160_SIGMA
A5376_SIGMA
A6810_SIGMA
AB1003266
AC 5230
AC1L1D8U
AC1Q1LA0
ACETYLSALICYLIC ACID
AI3-02956
AIN
AKOS000118884
ASA
Acenterine
Acesal
Acetal
Acetard
Aceticyl
Acetilsalicilico
Acetilum acidulatum
Acetisal
Acetol
Acetonyl
Acetophen
Acetosal
Acetosalic acid
Acetosalin
Acetoxybenzoic acid
Acetylin
Acetylsal
Acetylsalicylate
Acetylsalicylic acid
Acetylsalicylsaeure
Acetylsalicylsaure
Acetylsalycilic acid
Acetyonyl
Acetysal
Acetysalicylic acid
Acide 2-(acetyloxy)benzoique
Acide acetylsalicylique
Acide acétylsalicylique
Acido O-acetil-benzoico
Acido acetilsalicilico
Acidum acetylsalicylicum
Acimetten
Acisal
Acylpyrin
Adiro
Aloxiprimum
Asacard
Asagran
Asatard
Ascoden-30
Aspalon
Aspec
Aspergum
Aspir-Mox
Aspirdrops
Aspirin
Aspirin (JP15/USP)
Aspirin [BAN:JAN]
Aspirina 03
Aspirine
Asprin
Aspro
Aspro Clear
Asteric
Azetylsalizylsaeure
Azetylsalizylsäure
BIDD:GT0118
BRN 0779271
Bay-e-4465
Bayer
Bayer Aspirin 8 Hour
Bayer Buffered
Bayer Extra Strength Aspirin For Migraine Pain
Bayer Plus
Benaspir
Bi-prin
Bialpirina
Bialpirinia
Bufferin
C01405
CCRIS 3243
CHEBI:15365
CHEMBL25
CID2244
Caprin
Cardioaspirin
Cardioaspirina
Cemirit
Claradin
Clariprin
Colfarit
Contrheuma retard
Coricidin
Crystar
D00109
D001241
DB00945
Decaten
Delgesic
Dispril
DivK1c_000555
Dolean pH 8
Duramax
ECM
EINECS 200-064-1
EU-0100038
Easprin
Easprin (TN)
Ecolen
Ecotrin
Empirin
Empirin with Codeine
Endosprin
Endydol
 
Entericin
Enterophen
Enterosarein
Enterosarine
Entrophen
Extren
Globentyl
Globoid
HMS1920E13
HMS2090G03
HMS2091K13
HMS501L17
HSDB 652
Helicon
I14-7505
IDI1_000555
Idragin
Istopirin
KBio1_000555
KBio2_001725
KBio2_002271
KBio2_004293
KBio2_004839
KBio2_006861
KBio2_007407
KBio3_002149
KBio3_002751
KBioGR_000398
KBioGR_002271
KBioSS_001725
KBioSS_002272
Kapsazal
Kyselina 2-acetoxybenzoova
Kyselina acetylsalicylova
LS-143
Levius
Lopac-A-5376
Lopac0_000038
MLS001055329
MLS001066332
MLS001336045
MLS001336046
Magnecyl
Measurin
Medisyl
Micristin
MolPort-000-871-622
NCGC00015067-01
NCGC00015067-04
NCGC00015067-09
NCGC00090977-01
NCGC00090977-02
NCGC00090977-03
NCGC00090977-04
NCGC00090977-05
NCGC00090977-06
NCGC00090977-07
NCI60_002222
NINDS_000555
NSC 27223
NSC27223
NSC406186
Neuronika
Novid
Nu-seals
Nu-seals aspirin
O-(Acetyloxy)benzoate
O-(Acetyloxy)benzoic acid
O-Acetoxybenzoate
O-Acetoxybenzoic acid
O-Acetylsalicylic acid
O-Carboxyphenyl acetate
O-accetylsalicylic acid
O-acetylsalicylic acid
PL-2200
Persistin
Pharmacin
Pirseal
Polopirin
Polopiryna
Premaspin
R16CO5Y76E [UNII]
Rheumin tabletten
Rheumintabletten
Rhodine
Rhonal
Ronal
S-211
SMR000059138
SP 189
SPBio_001838
SPECTRUM1500130
ST075414
Salacetin
Salcetogen
Saletin
Salicylic acid acetate
Salicylic acid, acetate
Salospir
Solfrin
Solprin
Solprin acid
Solpyron
Solupsan
Spectrum2_001899
Spectrum3_001295
Spectrum4_000099
Spectrum5_000740
Spectrum_001245
Spira-Dine
St. Joseph
St. Joseph Aspirin for Adults
Supac
Tasprin
Temperal
Toldex
Triaminicin
Triple-sal
UNII R16CO5Y76E
UNII-R16CO5Y76E
UNII=R16CO5Y76E
UNM-0000306102
Vanquish
WLN: QVR BOV1
XAXA
Xaxa
Yasta
ZORprin
aspirin
cMAP_000006
component of Midol
component of Synirin
nchem.859-comp6
o-Acetoxybenzoic acid
o-Carboxyphenyl acetate
o-acetoxybenzoic acid
o-carboxyphenyl acetate
ácido acetilsalicílico
14
CilostazolapprovedPhase 410373963-72-12754
Synonyms:
3,4-Dihydro-6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-2(1H)-quinolinone
3,4-dihydro-6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-2(1H)-quinolinone
6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-2(1H)-quinolinone
6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydrocarbostyril
6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxyl)-3,4-dihydrocarobostyril
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-1H-quinolin-2-one
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-2(1H)-quinolinone
6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydroquinolin-2(1H)-one
6-[4-(1-cyclohexyltetrazol-5-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one
73963-72-1
89332-50-3
AC-4334
AC1L1EE2
BRD-K67017579-001-04-2
BRD-K67017579-001-05-9
BRD-K67017579-001-07-5
BRD-K67017579-001-13-3
BRN 3632107
BSPBio_002759
C 0737
C045645
C0737_SIGMA
C20H27N5O2
CHEBI:31401
CHEMBL799
CID2754
CL23867
CPD000058428
Cilostazol (JP15/USAN/INN)
Cilostazol [INN:JAN]
Cilostazole
Cilostazolum
Cilostazolum [INN-Latin]
D01896
DB01166
EU-0100218
HMS1922N15
HMS2093M14
KBio3_002259
KBioGR_001184
 
LS-142693
Lopac-C-0737
Lopac0_000218
MLS000028470
MLS000758281
MLS000759507
MLS001076067
MLS002153891
MolPort-001-758-007
NCGC00015207-01
NCGC00015207-02
NCGC00015207-06
NCGC00015207-10
NCGC00022153-02
NCGC00022153-04
NCGC00022153-05
NCGC00022153-06
NCGC00022153-07
OPC 13013
OPC 21
OPC-13013
OPC-21
Otsuka brand of cilostazol
Pletaal
Pletal
Pletal (TN)
Pletal, Cilostazol
S1294_Selleck
SAM001246734
SAM001247085
SMR000058428
SPBio_001256
SPECTRUM1505230
Spectrum2_001118
Spectrum3_001170
Spectrum4_000772
Spectrum5_001762
TL8005113
Tocris-1692
UNII-N7Z035406B
ZINC01552174
cilostazol
15Liver ExtractsPhase 4, Phase 33868
16HormonesPhase 4, Phase 2, Phase 3, Phase 113979
17Vasodilator AgentsPhase 43438
18Platelet Aggregation InhibitorsPhase 4, Phase 22419
19IncretinsPhase 4, Phase 2, Phase 3, Phase 11537
20Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 4, Phase 2, Phase 3, Phase 112767
21Hormone AntagonistsPhase 4, Phase 2, Phase 3, Phase 112778
22Insulin, Globin ZincPhase 4, Phase 3, Phase 2, Phase 14523
23Antihypertensive AgentsPhase 4, Phase 34095
24insulinPhase 4, Phase 3, Phase 2, Phase 14524
25AnalgesicsPhase 4, Phase 2, Phase 111287
26Analgesics, Non-NarcoticPhase 4, Phase 26260
27Pharmaceutical SolutionsPhase 4, Phase 3, Phase 27793
28Hypoglycemic AgentsPhase 4, Phase 2, Phase 3, Phase 15733
29Sitagliptin PhosphatePhase 4, Phase 3416
30Anti-Asthmatic AgentsPhase 4, Phase 13369
31Anti-Inflammatory Agents, Non-SteroidalPhase 4, Phase 24295
32Autonomic AgentsPhase 49774
33Antirheumatic AgentsPhase 4, Phase 2, Phase 110627
34Dipeptidyl-Peptidase IV InhibitorsPhase 4, Phase 3846
35Anticholesteremic AgentsPhase 41983
36Anti-Inflammatory AgentsPhase 4, Phase 210355
37
protease inhibitorsPhase 4, Phase 35320
Synonyms:
 
protease inhibitors
38Calcium, DietaryPhase 4, Phase 35525
39Atorvastatin CalciumPhase 4743134523-03-8
40Hydroxymethylglutaryl-CoA Reductase InhibitorsPhase 41956
41Immunosuppressive AgentsPhase 4, Phase 2, Phase 3, Phase 112770
42Hypolipidemic AgentsPhase 4, Phase 22721
43Anti-Arrhythmia AgentsPhase 4, Phase 2, Phase 32969
44Respiratory System AgentsPhase 4, Phase 2, Phase 14818
45HIV Protease InhibitorsPhase 4, Phase 35319
46Neurotransmitter AgentsPhase 4, Phase 2, Phase 117734
47AntimetabolitesPhase 4, Phase 211774
48Peripheral Nervous System AgentsPhase 4, Phase 2, Phase 122776
49Lipid Regulating AgentsPhase 4, Phase 22702
50Protective AgentsPhase 4, Phase 2, Phase 17190

Interventional clinical trials:

(show top 50)    (show all 159)
idNameStatusNCT IDPhase
1Thyroid Study Type 2 Diabetes Mellitus (T2DM)Unknown statusNCT01379170Phase 4
2Study of the Effect of Moxonidine and Diet on Sympathetic Functions in Young Adults With ObesityUnknown statusNCT01180231Phase 4
3Phenotypic and Genetic Correlates of Diabetes (Non-Type 1) in Young Non-Obese Asian Indians in North India and A Study to Evaluate the Efficacy of Sitagliptin (DPP-4 Inhibitor) in a Sub-group of the Study PopulationCompletedNCT00964184Phase 4
4Efficacy and Safety Study of Pitavastatin Compared to atoRvastatin in Type 2 dIabeTes Mellitus With HypercholesterolemiaCompletedNCT00889226Phase 4
5Management of Type-2 Diabetic Patients Treated With Insulin During the RamadanCompletedNCT01354925Phase 4
6Optimal Oral Hypoglycaemic Agents (OHA) for Combination With Insulin Glargine (Sulfonylurea vs. Metformin)CompletedNCT00708578Phase 4
7Insulin Glargine (Lantus) vs Sulfonylurea (SU) for BETA Cell Function (BETA Study)CompletedNCT00562172Phase 4
8Exenatide and Brown Adipose TissueRecruitingNCT03002675Phase 4
9Mirabegron and Brown Adipose TissueRecruitingNCT03012113Phase 4
10Effects of Dapagliflozin on Epicardial Fat in Subjects With Type 2 DiabetesRecruitingNCT02235298Phase 4
11Exploratory Study to Compare the Effects of Tenelia® or Januvia® on Glucose Variability in add-on to Metformin (CGMS Study)RecruitingNCT02512523Phase 4
12Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS)RecruitingNCT02500147Phase 4
13Diabetes Interventional Assessment of Slimming or Training to Lessen Inconspicuous Cardiovascular DysfunctionRecruitingNCT02590822Phase 4
14Metformin in Longevity StudyActive, not recruitingNCT02432287Phase 4
15Autoimmune Diabetes Accelerator Prevention TrialEnrolling by invitationNCT02881528Phase 4
16Effect of aSpirin Versus CilOstazol for Inhibition of Antiplatelet aggRegaTion in Type 2 DM PatientsNot yet recruitingNCT02933788Phase 4
17The Effects of Exenatide on Post-Meal Sugar Peaks and Vascular Health in Obese/Pre-Diabetic Young AdultsWithdrawnNCT00845559Phase 4
18The Effects of GLP-1 in Maturity-Onset Diabetes of The Young (MODY)CompletedNCT01610934Phase 2, Phase 3
19Safety and Efficacy of OSTEOFORM (rhPTH [1-34]) in Increasing Bone Mineral Density in OsteoporosisCompletedNCT00500409Phase 3
20Extension Study for 2993-112CompletedNCT01789957Phase 3
21Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With a SulfonylureaCompletedNCT00039026Phase 3
22Type 2 Diabetes Primary Prevention for At Risk GirlsCompletedNCT00063674Phase 2, Phase 3
23Phase III Study for Glimepiride + Metformin Hydrochloride (Amaryl M) Slow Release (SR)CompletedNCT00437554Phase 3
24Glibentek in Patients With Neonatal Diabetes Secondary to Mutations in K+-ATP ChannelsCompletedNCT02375828Phase 3
25Effects of Liraglutide in Young Adults With Type 2 DIAbetes (LYDIA)RecruitingNCT02043054Phase 3
26An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial HypertensionRecruitingNCT01560637Phase 3
27Trial of the Early Combination of Oral Treprostinil With Background Oral Monotherapy in Subjects With Pulmonary Arterial HypertensionRecruitingNCT01560624Phase 3
28Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid TreatmentRecruitingNCT02548351Phase 3
29Treating Insulin Resistance as a Strategy to Improve Outcome in Refractory Bipolar DisorderRecruitingNCT02519543Phase 3
30Effect Of Mesenchymal Stem Cells Transfusion on the Diabetic Peripheral Neuropathy Patients .Active, not recruitingNCT02387749Phase 2, Phase 3
31Mindfulness: a Novel Approach for the Management of Diabetes-related DistressActive, not recruitingNCT01805245Phase 2, Phase 3
32Effect of a Continuous Glucose Monitoring on Maternal and Neonatal Outcomes in Gestational Diabetes MellitusNot yet recruitingNCT02838147Phase 3
33Efficacy of Foot Orthotics in Veterans With Chronic Lower Back PainTerminatedNCT01865539Phase 2, Phase 3
34A Study to Determine the Safety & Efficacy of Autologous Human Platelet Lysate (HPL) in Treatment of Dark CirclesUnknown statusNCT01644448Phase 1, Phase 2
35The Effects of California Strawberries on Parameters of Cardiovascular HealthUnknown statusNCT01705093Phase 2
36Clinical Trial of YH14618 in Patients With Degenerative Disc DiseaseCompletedNCT02320019Phase 2
37Open-label Study of STA-9090 for Patients With Metastatic Breast CancerCompletedNCT01273896Phase 2
38RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARDCompletedNCT02128113Phase 2
39A Clinical Trial to Evaluate the Safety and Efficacy of ZYH7 Compared to Fenofibrate in Patients With DyslipidemiaCompletedNCT01539616Phase 2
40Partners for Better Health in Adolescent Type 2 Diabetes: The Buddy StudyCompletedNCT01007266Phase 2
41Stem Cell Educator Therapy in Type 2 DiabetesCompletedNCT01415726Phase 1, Phase 2
42Translating the DPP Into the CommunityCompletedNCT00302042Phase 2
43A Study to Assess the PK and Pharmacodynamics of IPX203 in Subjects With Advanced Parkinson's DiseaseRecruitingNCT03007888Phase 2
44Mobile Device Outcomes-based Rehabilitation ProgramRecruitingNCT02891707Phase 1, Phase 2
45N-Acetyl Cysteine and Aspirin as an Adjunctive Treatment for Bipolar DisorderRecruitingNCT01797575Phase 2
46Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)RecruitingNCT02766465Phase 2
47Double-blinded, 6 Months Study With Bydureon® or Placebo in Adolescents With Obesity to Explore Changes in BMIActive, not recruitingNCT02794402Phase 2
48Theophylline Treatment for PseudohypoparathyroidismNot yet recruitingNCT03029429Phase 2
49Hypogonadism in Young Men With Type 2 DiabetesTerminatedNCT01155518Phase 2
50Evaluate Safety and Effectiveness of MBX-102 in Type 2 Diabetes Patients With Poor Glycemic Control on MetforminTerminatedNCT00814372Phase 2

Search NIH Clinical Center for Maturity-Onset Diabetes of the Young

Genetic Tests for Maturity-Onset Diabetes of the Young

About this section

Genetic tests related to Maturity-Onset Diabetes of the Young:

id Genetic test Affiliating Genes
1 Maturity Onset Diabetes Mellitus in Young26
2 Maturity-Onset Diabetes of the Young26 24

Anatomical Context for Maturity-Onset Diabetes of the Young

About this section

MalaCards organs/tissues related to Maturity-Onset Diabetes of the Young:

35
Bone, Brain, Testes, Liver, Bone marrow, Endothelial, Ovary

Animal Models for Maturity-Onset Diabetes of the Young or affiliated genes

About this section

MGI Mouse Phenotypes related to Maturity-Onset Diabetes of the Young:

40 (show all 15)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:000538110.6CEL, FOXA2, HNF1A, INS, NEUROD1, NEUROG3
2MP:000537510.6APPL1, CEL, FOXA2, HNF1A, INS, KCNJ11
3MP:000536910.6APPL1, HNF1A, HNF1B, INS, KCNJ11, PDX1
4MP:000536710.6GCK, HNF1A, HNF1B, INS, NEUROD1, NEUROG3
5MP:000301210.6ABCC8, APPL1, HNF1A, INS, KCNJ11, NEUROG3
6MP:000537010.4CEL, FOXA2, GCK, HNF1A, HNF1B, HNF4A
7MP:000538410.3APPL1, FOXA2, HNF1A, HNF4A, INS, NEUROD1
8MP:000287310.2BLK, FOXA2, HNF4A, INS, KLF11, NEUROG3
9MP:00053799.8ABCC8, BLK, FOXA2, GCK, HNF1A, HNF1B
10MP:00053789.7APPL1, CEL, FOXA2, GCK, HNF1A, HNF1B
11MP:00107689.7APPL1, FOXA2, GCK, HNF1A, HNF1B, HNF4A
12MP:00053769.3ABCC8, APPL1, CEL, FOXA2, GCK, GCKR

Publications for Maturity-Onset Diabetes of the Young

About this section

Articles related to Maturity-Onset Diabetes of the Young:

(show top 50)    (show all 308)
idTitleAuthorsYear
1
Searching for Maturity-Onset Diabetes of the Young (MODY): When and What for? (27103109)
2016
2
Studies of genetic variability of the hepatocyte nuclear factor-1I+ gene in an Indian maturity-onset diabetes of the young family. (27148439)
2016
3
A review of maturity onset diabetes of the young (MODY) and challenges in the management of glucokinase-MODY. (27852188)
2016
4
A three-step programmed method for the identification of causative gene mutations of maturity onset diabetes of the young (MODY). (27185633)
2016
5
Maturity onset diabetes of the young 5 accompanied by duodenal cysts. (26676964)
2016
6
The complexity of elucidating whether novel mutations in the hepatocyte nuclear factor one alpha gene are responsible for maturity onset diabetes of the young in ethnic minorities. (26393317)
2015
7
Molecular and clinical characterization of glucokinase maturity-onset diabetes of the young (GCK-MODY) in Japanese patients. (24804978)
2014
8
Incretin effect and glucagon responses to oral and intravenous glucose in patients with maturity-onset diabetes of the young--type 2 and type 3. (24677712)
2014
9
Exocrine pancreatic function in hepatocyte nuclear factor 1I^-maturity-onset diabetes of the young (HNF1B-MODY) is only moderately reduced: compensatory hypersecretion from a hypoplastic pancreas. (23600988)
2013
10
GCK Mutation in a Child with Maturity Onset Diabetes of the Young, Type 2. (23724189)
2013
11
Molecular diagnosis of maturity onset diabetes of the young in India. (23869298)
2013
12
Metabolic profiling in Maturity-onset diabetes of the young (MODY) and young onset type 2 diabetes fails to detect robust urinary biomarkers. (22859960)
2012
13
A Case of Novel Mutation of HNF1B in Maturity-onset Diabetes of the Young Type 5 (MODY5). (23926411)
2012
14
Clinical features and treatment of maturity onset diabetes of the young (MODY). (22654519)
2012
15
Clinical characteristics and diagnostic criteria of maturity-onset diabetes of the young (MODY) due to molecular anomalies of the HNF1A gene. (21677039)
2011
16
Islet autoantibodies can discriminate maturity-onset diabetes of the young (MODY) from Type 1 diabetes. (21395678)
2011
17
Hepatocyte nuclear factor 4I+ gene mutation associated with familial neonatal hyperinsulinism and maturity-onset diabetes of the young. (21353246)
2011
18
Pancreatic exocrine dysfunction in maturity-onset diabetes of the young type 3. (17989309)
2008
19
Common variants in maturity-onset diabetes of the young genes and future risk of type 2 diabetes. (18332101)
2008
20
Partial and whole gene deletion mutations of the GCK and HNF1A genes in maturity-onset diabetes of the young. (17828387)
2007
21
Exonic duplication of the hepatocyte nuclear factor-1beta gene (transcription factor 2, hepatic) as a cause of maturity onset diabetes of the young type 5. (17440011)
2007
22
Digenic inheritance of hepatocyte nuclear factor-1alpha and -1beta with maturity-onset diabetes of the young, polycystic thyroid, and urogenital malformations. (17337496)
2007
23
From clinicogenetic studies of maturity-onset diabetes of the young to unraveling complex mechanisms of glucokinase regulation. (16731834)
2006
24
Identification of novel and recurrent glucokinase mutations in Belgian and Luxembourg maturity onset diabetes of the young patients. (16965331)
2006
25
Hepatocyte nuclear factor-1 alpha gene inactivation: cosegregation between liver adenomatosis and diabetes phenotypes in two maturity-onset diabetes of the young (MODY)3 families. (15001650)
2004
26
Maturity-onset diabetes of the young with end-stage nephropathy: a new indication for simultaneous pancreas and kidney transplantation? (15114102)
2004
27
Identification of eight novel glucokinase mutations in Italian children with maturity-onset diabetes of the young. (12955723)
2003
28
Regulation of pancreatic beta-cell function by the HNF transcription network: lessons from maturity-onset diabetes of the young (MODY). (14614204)
2003
29
Prevalence of maturity-onset diabetes of the young mutations in Brazilian families with autosomal-dominant early-onset type 2 diabetes. (11315851)
2001
30
Maturity onset diabetes of the young as a model for complex disease. (11485013)
2001
31
Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. (11575290)
2001
32
Genetic and clinical characterisation of maturity-onset diabetes of the young in Spanish families. (10754480)
2000
33
Autoregulation and maturity onset diabetes of the young transcription factors control the human PAX4 promoter. (10967107)
2000
34
Functional properties of the R154X HNF-4alpha protein generated by a mutation associated with maturity-onset diabetes of the young, type 1. (10940385)
2000
35
Allelic drop-out in exon 2 of the hepatocyte nuclear factor-1alpha gene hinders the identification of mutations in three families with maturity-onset diabetes of the young. (10102714)
1999
36
Genetic testing for maturity onset diabetes of the young in childhood hyperglycaemia. (9713013)
1998
37
Glucose utilization and production in patients with maturity-onset diabetes of the young caused by a mutation of the hepatocyte nuclear factor-1alpha gene. (9726235)
1998
38
Maturity-onset diabetes of the young (MODY), MODY genes and non-insulin-dependent diabetes mellitus. (9162575)
1997
39
Diabetic lipemia with maturity-onset diabetes of the young. (9260775)
1997
40
The maturity-onset diabetes of the young (MODY1) transcription factor HNF4alpha regulates expression of genes required for glucose transport and metabolism. (9371825)
1997
41
An automated fluorescent single-strand conformation polymorphism technique for screening mutations in the hepatocyte nuclear factor- 1alpha gene (maturity-onset diabetes of the young). (9392505)
1997
42
Maturity onset diabetes of the young (MODY). (8894490)
1996
43
Maturity onset diabetes of the young. (11256912)
1995
44
A gene for maturity onset diabetes of the young (MODY) maps to chromosome 12q. (7795649)
1995
45
Identification of genetic markers flanking the locus for maturity-onset diabetes of the young on human chromosome 20. (1345781)
1992
46
Primary pancreatic beta-cell secretory defect caused by mutations in glucokinase gene in kindreds of maturity onset diabetes of the young. (1354782)
1992
47
Maturity onset diabetes of the young in a Saudi child: Case report and review of the literature. (17590827)
1991
48
Maturity-onset diabetes of the young (MODY). (2689121)
1989
49
C-Peptide responses to glucose load in maturity-onset diabetes of the young (MODY). (3882370)
1985
50
Diabetic nephropathy in a patient with maturity-onset diabetes of the young. (7235789)
1981

Variations for Maturity-Onset Diabetes of the Young

About this section

Expression for genes affiliated with Maturity-Onset Diabetes of the Young

About this section
Search GEO for disease gene expression data for Maturity-Onset Diabetes of the Young.

Pathways for genes affiliated with Maturity-Onset Diabetes of the Young

About this section

Pathways related to Maturity-Onset Diabetes of the Young according to KEGG:

33
id Name KEGG Source Accession
1Maturity onset diabetes of the younghsa04950

Pathways related to Maturity-Onset Diabetes of the Young according to GeneCards Suite gene sharing:

idSuper pathwaysScoreTop Affiliating Genes
110.3HNF1A, HNF4A
2
Show member pathways
9.9ABCC8, INS, KCNJ11, PKLR, SLC2A2
3
Show member pathways
9.9ABCC8, GCK, INS, KCNJ11, PDX1, SLC2A2
49.8FOXA2, GCKR, HNF1A, HNF4A, INS, NEUROD1
5
Show member pathways
9.6FOXA2, GCK, HNF1A, HNF1B, HNF4A, INS
69.5FOXA2, HNF1B, INS, NEUROD1, NEUROG3, NKX2-2
79.4ABCC8, FOXA2, GCK, HNF1A, HNF4A, INS
8
Show member pathways
9.3ABCC8, GCK, HNF1A, HNF1B, HNF4A, INS
9
Show member pathways
9.1FOXA2, GCK, HNF1A, HNF1B, HNF4A, INS
10
Show member pathways
9.1FOXA2, GCK, HNF1A, HNF1B, HNF4A, INS

GO Terms for genes affiliated with Maturity-Onset Diabetes of the Young

About this section

Cellular components related to Maturity-Onset Diabetes of the Young according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1nucleusGO:00056349.1APPL1, FOXA2, GCK, GCKR, HNF1A, HNF1B

Biological processes related to Maturity-Onset Diabetes of the Young according to GeneCards Suite gene sharing:

(show all 36)
idNameGO IDScoreTop Affiliating Genes
1regulation of pronephros sizeGO:003556511.0HNF1A, HNF1B
2detection of glucoseGO:005159411.0GCK, PDX1
3positive regulation of glycolytic processGO:004582111.0GCK, INS
4positive regulation of transcription initiation from RNA polymerase II promoterGO:006026111.0HNF1A, HNF1B
5pancreatic A cell fate commitmentGO:000332611.0NEUROD1, NKX2-2
6pancreatic PP cell fate commitmentGO:000332911.0NEUROD1, NKX2-2
7positive regulation of glycogen biosynthetic processGO:004572511.0GCK, INS
8negative regulation of type B pancreatic cell apoptotic processGO:200067510.9NEUROD1, PDX1
9cellular glucose homeostasisGO:000167810.9GCK, GCKR
10negative regulation of gluconeogenesisGO:004572110.9GCK, INS
11transdifferentiationGO:006029010.9NEUROG3, PDX1
12signal transduction involved in regulation of gene expressionGO:002301910.8HNF4A, NEUROD1
13glucose transportGO:001575810.8GCK, INS, SLC2A2
14negative regulation of glucokinase activityGO:003313210.8FOXA2, GCKR
15nitric oxide mediated signal transductionGO:000726310.8NEUROD1, PDX1
16regulation of Wnt signaling pathwayGO:003011110.7HNF1A, HNF1B
17liver developmentGO:000188910.7HNF1A, HNF1B, PDX1
18insulin secretionGO:003007310.6HNF1A, HNF1B, NEUROD1, PDX1
19hindbrain developmentGO:003090210.6HNF1B, NEUROD1, NEUROG3
20response to cAMPGO:005159110.6HNF4A, PAX4, PKLR
21positive regulation of sequence-specific DNA binding transcription factor activityGO:005109110.6NEUROD1, NEUROG3, NKX2-2
22positive regulation of insulin secretionGO:003202410.5BLK, GCK, PDX1
23glucose metabolic processGO:000600610.5GCK, INS, KCNJ11, PDX1
24response to organic cyclic compoundGO:001407010.4HNF1B, NKX2-2, PDX1, PKLR
25positive regulation of cell differentiationGO:004559710.4INS, NEUROD1, NEUROG3, NKX2-2, PAX4
26glucose homeostasisGO:004259310.4GCK, HNF1A, HNF4A, INS, NEUROD1, PDX1
27endocrine pancreas developmentGO:003101810.4FOXA2, HNF1A, NEUROD1, NEUROG3, NKX2-2, PAX4
28transcription from RNA polymerase II promoterGO:000636610.4HNF1A, KLF11, NEUROD1, NEUROG3, PDX1
29regulation of insulin secretionGO:005079610.4ABCC8, GCK, HNF1A, HNF4A, KCNJ11, NEUROD1
30positive regulation of neuron differentiationGO:004566610.3NEUROD1, NEUROG3, NKX2-2
31response to ATPGO:003319810.3KCNJ11, PKLR
32positive regulation of transcription, DNA-templatedGO:004589310.2FOXA2, HNF1A, HNF1B, HNF4A, NEUROD1, PDX1
33response to glucoseGO:000974910.1HNF1A, HNF1B, HNF4A, NEUROD1, NKX2-2, PDX1
34cell differentiationGO:003015410.1BLK, HNF4A, NKX2-2, PAX4, PDX1
35positive regulation of transcription from RNA polymerase II promoterGO:00459449.6FOXA2, HNF1A, HNF1B, HNF4A, NEUROD1, NEUROG3
36response to drugGO:00424939.5ABCC8, HNF1B, HNF4A, KCNJ11, NEUROD1, PAX4

Molecular functions related to Maturity-Onset Diabetes of the Young according to GeneCards Suite gene sharing:

(show all 10)
idNameGO IDScoreTop Affiliating Genes
1ATP-activated inward rectifier potassium channel activityGO:001527211.0ABCC8, KCNJ11
2core promoter proximal region DNA bindingGO:000115910.9HNF1B, NKX2-2
3potassium ion bindingGO:003095510.8KCNJ11, PKLR
4transcription factor activity, RNA polymerase II distal enhancer sequence-specific bindingGO:000370510.7HNF1B, HNF4A, PDX1
5transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific bindingGO:000107710.5HNF1A, HNF4A, NEUROD1, NEUROG3
6double-stranded DNA bindingGO:000369010.2HNF1A, NEUROD1, NEUROG3, PAX4
7transcription regulatory region DNA bindingGO:004421210.1FOXA2, HNF1A, HNF1B, HNF4A, KLF11
8sequence-specific DNA bindingGO:00435659.9HNF1A, HNF1B, HNF4A, NEUROD1, NKX2-2, PDX1
9transcription factor bindingGO:00081349.7FOXA2, HNF1A, NEUROD1, NKX2-2, PDX1
10transcription factor activity, sequence-specific DNA bindingGO:00037009.4FOXA2, HNF1A, HNF1B, HNF4A, KLF11, NEUROD1

Sources for Maturity-Onset Diabetes of the Young

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
26GTR
27HGMD
28HMDB
29ICD10
30ICD10 via Orphanet
31ICD9CM
32IUPHAR
33KEGG
36MedGen
38MeSH
39MESH via Orphanet
40MGI
43NCI
44NCIt
45NDF-RT
48NINDS
49Novoseek
51OMIM
52OMIM via Orphanet
56PubMed
57QIAGEN
62SNOMED-CT via Orphanet
66Tumor Gene Family of Databases
67UMLS
68UMLS via Orphanet